secwatch.observer — SEC 8-K summary
======================================

Issuer:     PROKIDNEY CORP. (PROK)
CIK:        0001850270
Form:       8-K
Filed at:   2025-08-12T23:59:59+00:00
Accession:  0000950170-25-107357
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ProKidney Q2 net loss $37M; FDA agrees eGFR slope for accelerated approval; Phase 2 shows 78% eGFR improvement
--------------------------------------------------------------------------------

- FDA confirmed eGFR slope as surrogate endpoint for accelerated approval of rilparencel; topline data from PROACT 1 expected Q2 2027.
- Phase 2 REGEN-007: eGFR slope improved 78% (from -5.8 to -1.3 mL/min/1.73m²/yr) in Group 1 (n=24), p<0.001; no SAEs related.
- Cash and equivalents $294.7M as of June 30, 2025, down from $328.5M; funds operations into mid-2027.
- Q2 net loss $37.0M vs $38.5M in prior year; R&D expenses $25.9M down from $29.4M.
- More than half of ~350 patients for accelerated approval analysis enrolled in Phase 3 PROACT 1.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1850270/000095017025107357/0000950170-25-107357-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1850270/000095017025107357/prok-20250812.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-107357

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer